GE91 Stock Overview
A biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for GE91 from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Genmab A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 21.00 |
| 52 Week High | DKK 28.80 |
| 52 Week Low | DKK 18.10 |
| Beta | 0.86 |
| 1 Month Change | 5.00% |
| 3 Month Change | 7.69% |
| 1 Year Change | -21.64% |
| 3 Year Change | -27.59% |
| 5 Year Change | n/a |
| Change since IPO | -23.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| GE91 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.5% | -12.3% | -0.6% |
| 1Y | -21.6% | -15.3% | 14.8% |
Return vs Industry: GE91 underperformed the German Biotechs industry which returned -15.3% over the past year.
Return vs Market: GE91 underperformed the German Market which returned 14.8% over the past year.
Price Volatility
| GE91 volatility | |
|---|---|
| GE91 Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: GE91 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: GE91's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 2,682 | Jan G.J. de Winkel | www.genmab.com |
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors.
Genmab A/S Fundamentals Summary
| GE91 fundamental statistics | |
|---|---|
| Market cap | €13.49b |
| Earnings (TTM) | €1.05b |
| Revenue (TTM) | €2.89b |
12.8x
P/E Ratio4.7x
P/S RatioIs GE91 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GE91 income statement (TTM) | |
|---|---|
| Revenue | DKK 21.53b |
| Cost of Revenue | DKK 985.00m |
| Gross Profit | DKK 20.54b |
| Other Expenses | DKK 12.70b |
| Earnings | DKK 7.84b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 08, 2025
| Earnings per share (EPS) | 123.45 |
| Gross Margin | 95.42% |
| Net Profit Margin | 36.44% |
| Debt/Equity Ratio | 0% |
How did GE91 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 14:46 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genmab A/S is covered by 45 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Carlsen | ABG Sundal Collier |
| Armelle Moulin | AlphaValue |
| Emily Field | Barclays |